Studies in CLL have shown that combining venetoclax with anti-CD20 monoclonal antibodies (rituximab or obinutuzumab), Bruton-tyrosine kinase inhibitors (BTKi), and PI3Ki can overcome resistance to venetoclax[26,31]. Here, MS4A1 is linked to B-cell chronic lymphocytic leukemia.